This is a StreetInsider.com Premium Only Page

Biogen (BIIB) – PRNewswire

Mar 31, 2024 07:30 PM Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA

Jan 3, 2024 08:00 AM Alcyone Therapeutics Announces First Patient Implanted in PIERRE IDE Clinical Study of the ThecaFlex DRx™ System for Administration of SPINRAZA® (nusinersen)

Oct 25, 2023 05:25 PM EISAI PRESENTS NEW LEQEMBI® (LECANEMAB-IRMB) INVESTIGATIONAL SUBCUTANEOUS FORMULATION INTERIM STUDY RESULTS AND CLINICAL IMPROVEMENT DATA IN EARLIER STAGES OF EARLY ALZHEIMER'S DISEASE FROM ADDITIONA

Oct 24, 2023 09:30 AM LEQEMBI® (lecanemab-irmb) NAMED ONE OF TIME's BEST INVENTIONS OF 2023

Jul 19, 2023 07:30 PM Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023

Jul 6, 2023 08:00 PM FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer's Disease

Jun 27, 2023 07:00 AM Alcyone Therapeutics Receives FDA IDE Approval to Initiate Clinical Study of the ThecaFlex DRxTM System for Administration of SPINRAZA® (nusinersen)

Jun 9, 2023 06:45 PM FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer's Disease

May 15, 2023 07:00 AM Recurrent Energy Signs Aggregation Deal for 100 MW of Solar Energy in Texas with Industry Consortium

Mar 30, 2023 07:31 PM ADDITIONAL DETAILED ANALYSES FROM PHASE 2 STUDY 201 OF LECANEMAB PUBLISHED AS THREE PAPERS IN PEER-REVIEWED JOURNALS

Mar 30, 2023 07:30 PM EISAI PRESENTED NEW ANALYSES OF ARIA AND QOL ON LECANEMAB IN CLARITY AD AT THE AD/PD™ 2023 ANNUAL MEETING

Mar 5, 2023 06:30 PM FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's Disease

Feb 27, 2023 06:30 PM BIOLOGICS LICENSE APPLICATION FOR LECANEMAB DESIGNATED FOR PRIORITY REVIEW BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION

Jan 29, 2023 06:30 PM LECANEMAB RECEIVES PRIORITY REVIEW STATUS IN JAPAN

Jan 26, 2023 06:30 PM MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER'S DISEASE ACCEPTED BY EUROPEAN MEDICINES AGENCY

Jan 15, 2023 07:30 PM EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LECANEMAB FOR EARLY ALZHEIMER'S DISEASE IN JAPAN

Jan 10, 2023 06:30 PM EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER'S DISEASE IN EUROPE

Jan 6, 2023 11:30 PM Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's Disease

Jan 6, 2023 02:30 PM FDA Approves LEQEMBI™ (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease

Dec 22, 2022 06:45 PM EISAI INITIATES BLA SUBMISSION OF DATA FOR LECANEMAB IN CHINA

Nov 29, 2022 07:50 PM ELEVEN EXPERTS FROM LEADING MEDICAL INSTITUTIONS AND EIGHT EXPERTS FROM EISAI* PUBLISH FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER'S DISEASE IN THE NEW ENGLAND

Nov 29, 2022 07:50 PM EISAI PRESENTS FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER'S DISEASE AT CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE

Sep 27, 2022 07:30 PM LECANEMAB CONFIRMATORY PHASE 3 CLARITY AD STUDY MET PRIMARY ENDPOINT, SHOWING HIGHLY STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN LARGE GLOBAL CLINICAL STUDY OF 1,795 PARTICIPANTS WITH E

Aug 3, 2022 07:32 PM EISAI PRESENTS NEW FINDINGS ON LECANEMAB'S INVESTIGATIONAL SUBCUTANEOUS FORMULATION AND MODELING SIMULATION OF APOE4 GENOTYPE ON ARIA-E INCIDENCE AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENC

Jul 5, 2022 07:30 PM THE U.S. FDA ACCEPTS AND GRANTS PRIORITY REVIEW FOR EISAI'S BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY

May 9, 2022 07:31 PM EISAI COMPLETES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY

Mar 28, 2022 07:30 AM Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis

Mar 23, 2022 11:43 AM BIOGEN INC. (NASDAQ: BIIB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Biogen

Mar 21, 2022 07:30 PM LATEST FINDINGS ON LECANEMAB - CLINICAL EFFICACY, ARIA RATES, BIOMARKERS RELATIONSHIP TO CLINICAL OUTCOMES AND DOSING REGIMENS - PRESENTED AT AD/PD™ 2022 ANNUAL MEETING

Mar 4, 2022 06:39 PM Charles Schwab Set to Join S&P 100; BellRing Brands to Join S&P MidCap 400; Cerence to Join S&P SmallCap 600

Mar 3, 2022 06:30 PM EISAI INITIATES SUBMISSION OF APPLICATION DATA UNDER THE PRIOR ASSESSMENT CONSULTATION SYSTEM IN JAPAN WITH THE AIM OF OBTAINING EARLY APPROVAL FOR INVESTIGATIONAL ANTI-AMYLOID BETA PROTOFIBRIL ANTIBO

Feb 8, 2022 06:09 PM BIOGEN INC. (NASDAQ: BIIB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc. (NASDAQ: BIIB)

Jan 4, 2022 07:30 AM Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA

Dec 23, 2021 06:30 PM INVESTIGATIONAL ALZHEIMER'S DISEASE THERAPY LECANEMAB GRANTED FDA FAST TRACK DESIGNATION

Nov 11, 2021 12:00 PM Introduction of First-Of-A-Kind Plasma-Based Biomarker Screening To Facilitate Identification Of Subjects For Phase 3 Ahead 3-45 Trial Presented At Clinical Trials On Alzheimer's Disease (CTAD) Confer

Nov 11, 2021 11:20 AM Eisai Presents New Analysis Of Lecanemab Clinical Efficacy Results From Phase 2b Study At Clinical Trials On Alzheimer's Disease (CTAD) Conference

Nov 10, 2021 02:57 PM Eisai Presents Late-Breaker Updates On Lecanemab Clinical, Biomarker And Safety Data From Phase 2b Study Core And Open-Label Extension Across Five Years At Clinical Trials On Alzheimer's Disease (CTAD

Sep 27, 2021 07:30 PM Eisai Initiates Rolling Submission To The U.S. FDA For Biologics License Application Of Lecanemab (BAN2401) For Early Alzheimer's Disease Under The Accelerated Approval Pathway

Jul 29, 2021 04:30 PM Late-Breaking AAIC Presentation Explores Potential Clinical Effects Of Lecanemab (BAN2401)

Jul 26, 2021 04:35 PM Biogen and Ionis report positive topline clinical data on investigational Alzheimer's disease treatment at AAIC

Jul 21, 2021 08:03 AM Mirimus, Inc. Forms Strategic Collaboration with Biogen to Develop RNAi-Based Therapeutics for Neurological Disease Indications

Jun 29, 2021 08:53 AM Enel X Collaborates With Biogen To Electrify Take-home Vehicle Fleet In North America

Jun 23, 2021 04:06 PM Eisai And Biogen Inc. Announce U.S. FDA Grants Breakthrough Therapy Designation For Lecanemab (BAN2401), An Anti-Amyloid Beta Protofibril Antibody For The Treatment Of Alzheimer's Disease

Apr 19, 2021 07:38 PM 18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer's Disease Published in Peer-Reviewed Jo

Dec 15, 2020 07:00 PM APRINOIA Therapeutics Established Collaboration on Tau PET Imaging Tracer Development

Dec 10, 2020 11:30 AM DEADLINE ALERT for BABA, BIIB, YY, LRN: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Nov 23, 2020 04:00 AM ISD Immunotech, a Novo Seeds Portfolio Company, Enters Strategic Research Collaboration for the Development of a Novel Lupus Treatment

Oct 20, 2020 11:39 AM Abarca Details First Value-Based Agreement For Medicaid Members Prescribed Biogen Products

Sep 3, 2020 09:22 AM OneUnited Bank, Fintech Pioneer, Announces $10 Million Deposit By Biogen To Support #BankBlack Movement

Jul 13, 2020 07:31 PM Initiation Of New Phase III Clinical Study (AHEAD 3-45) Of BAN2401 Preclinical (Asymptomatic) Alzheimer's Disease